{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:06:59Z","timestamp":1758636419495,"version":"3.37.3"},"reference-count":37,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T00:00:00Z","timestamp":1497398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The objective of this study is to specify the most reported adverse events as preferred terms (PTs) and to compare the reported adverse events about some properties including the number of report and time\u2010to\u2010onset (TTO) distribution of the originator of filgrastim Neupogen\u00ae and its biosimilars in Europe, using VigiBase\u00ae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified the biosimilar which was reported as the suspected drug in more than 100 individual case safety reports in Europe. Then, we specified the top ranking 10 PTs in the cases reported with Neupogen\u00ae or each biosimilar as the suspected drug. We also compared the TTO of the most reported PTs using the data about the onset date of the PT and the start date of filgrastim. We used Kolmogorov\u2013Smirnov method to detect significant difference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The total ICSR numbers with Neupogen\u00ae and 3 biosimilars, Zarzio\u00ae, Nivestim\u00ae, and Tevagrastim\u00ae were 1,301, 295, 156, and 127, respectively, in Europe. The most reported PTs with Neupogen\u00ae were bone pain, pyrexia, and dyspnoea. The TTO of bone pain and pyrexia with Zarzio\u00ae (N: 22 and 16, median: 1 and 0.5 days) were significantly shorter than those with Neupogen\u00ae (P &lt; 0.01, N: 72 and 33, median: 3.5 and 3 days), respectively. The most reported PTs with biosimilars were drug ineffective and neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The difference in the TTO was identified between originator filgrastim Neupogen and its biosimilar regarding some PTs, which may suggest the difference in their safety profile. Copyright \u00a9 2017 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4218","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T09:25:04Z","timestamp":1497432304000},"page":"917-924","source":"Crossref","is-referenced-by-count":7,"title":["Comparative study of the number of report and time\u2010to\u2010onset of the reported adverse event between the biosimilars and the originator of filgrastim"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5600","authenticated-orcid":false,"given":"Tetsu","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Division of Biological Chemistry and Biologicals National Institute of Health Sciences  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Kamada","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Musashino University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Komura","sequence":"additional","affiliation":[{"name":"Office of Safety I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Musashino University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishii\u2010Watabe","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals National Institute of Health Sciences  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1948"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0121-z"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.770472"},{"key":"e_1_2_9_5_1","unstructured":"Annex 1 summary of product characteristicshttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000917\/WC500046525.pdf[accessed 14 July 2016]"},{"key":"e_1_2_9_6_1","unstructured":"European public assessment reportshttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&source=homeMedSearch&keyword=filgrastim&category=human&isNewQuery=true[accessed 17 November 2016]"},{"key":"e_1_2_9_7_1","unstructured":"Revision of PRECAUTIONS (FY2016) 13 September 2016http:\/\/www.pmda.go.jp\/english\/safety\/info\u2010services\/drugs\/revision\u2010of\u2010precautions\/0004.html[accessed 17 November 2016]"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-332"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1936"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1107285"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3746"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425744"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0190-9"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2861-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw309"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0419-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.033"},{"key":"e_1_2_9_18_1","first-page":"17","article-title":"Biosimilars in the management of neutropenia: focus on filgrastim","volume":"10","author":"Caselli D","year":"2016","journal-title":"Biologics"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_2_9_20_1","first-page":"436","article-title":"Comparative study of viral infection profiles during treatment with antibody pharmaceuticals and various immunosuppressants and risk analysis of viral infection","volume":"45","author":"Kobayashi T","year":"2014","journal-title":"Pharma and Medical Device Regulatory Sci"},{"key":"e_1_2_9_21_1","first-page":"45","article-title":"Comparative study of the time period between the initiation of various interferon therapies and the onset of suicide or diabetes\u2010related side effects","volume":"131","author":"Kobayashi T","year":"2013","journal-title":"Bull Natl Inst Health Sci"},{"key":"e_1_2_9_22_1","unstructured":"International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH E2E: Pharmacovigilance Planning.2004;http:\/\/www.pmda.go.jp\/files\/000156732.pdf[accessed 6 April 2016]"},{"key":"e_1_2_9_23_1","unstructured":"Notifications No. 0411\u20101 and 2 11 April 2012 issued by the Safety Division Manager and Evaluation and Licensing Division Manager Pharmaceutical and Food Safety Bureau Ministry of Health Labour and Welfare (Japanese)http:\/\/www.pmda.go.jp\/files\/000145482.pdf[accessed 6 April 2016]"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3820\/jjpe.19.103"},{"key":"e_1_2_9_25_1","unstructured":"Kyowa Hakko Kirin Co. Ltd.5 August 2015 Risk management plan for G lasta subcutaneous injection.http:\/\/www.pmda.go.jp\/files\/000207719.pdf(Japanese) [accessed 12 May 2016]"},{"key":"e_1_2_9_26_1","unstructured":"EMA\/187414\/2015 26 February 2015 Assessment Report Ristempa.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Public_assessment_report\/human\/003910\/WC500185707.pdf[accessed 14 July 2016]"},{"key":"e_1_2_9_27_1","unstructured":"EMEA\/CHMP 25 July 2013 Assessment Report GRASTOFIL.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Public_assessment_report\/human\/002150\/WC500154066.pdf[accessed 12 May 2016]"},{"key":"e_1_2_9_28_1","unstructured":"EMA\/475472\/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim).http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Risk\u2010management\u2010plan_summary\/human\/003956\/WC500169991.pdf[accessed 12 May 2016]"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina47080064"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt091"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12770"},{"key":"e_1_2_9_32_1","first-page":"478","article-title":"Safety and efficacy of granulocyte colony\u2010stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4\u2010year, single institute experience with different conditioning regimens","volume":"13","author":"Bassi S","year":"2015","journal-title":"Blood Transfus"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2986-0"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0224-1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S81998"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3998"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0237-9"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3502"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:21:27Z","timestamp":1696504887000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/pds.4218"],"URL":"https:\/\/doi.org\/10.1002\/pds.4218","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2017,6,14]]}}}